USP9x-deficient HCT116 (with or without p53) cell line
Invented at Johns Hopkins University
- Datasheet
- References (1)
- Inventor Info
Info
| Catalogue Number | 156403 |
| Antigen/Gene or Protein Targets | USP9X and p53 |
| Parental Line | HCT 116 |
| Tissue | Colon |
| Disease Keywords | Cancer |
| Model | Knock-Out |
| Relevance |
This cell line presents an opportunity to study the effect of loss of apoptotic control on colorectal cancer cells. Study of deubiquitinase Ups9X could act as a leap towards understanding apoptotic regulation and potentially lead to new drug targets for cancer. In this technology, the gene USP9X is knocked out of two the HCT116 cell line. The gene knockout has been performed by rAAV-mediated homologous recombination. The technology also consists of a double knockout line without USP9X and p53, a tumor suppressor gene. |
| Research Area | Cancer, Drug Discovery & Development |
